Atrial fibrillation: diagnosis and management

made based on the symptoms, heart rate, comorbidities and preferences of those being treated. The committee agreed that the recommendations should refer to NICE's guideline on chronic heart failure for advice on using beta-blockers and avoiding rate-limiting calcium-channel blockers such as diltiazem and verapamil in people who have atrial fibrillation with heart failure. The committee agreed that digoxin monotherapy for non-paroxysmal atrial fibrillation should continue to be considered for people who are sedentary. Based on their experience, the committee agreed that it may also be considered as a treatment option when other rate-limiting drugs are not suitable, so they expanded the recommendation in the previous guideline to also cover these circumstances. The committee were aware that some clinicians feel that digoxin monotherapy is often better than alternatives for improving symptoms; however, the lack of evidence currently available meant that the recommendation for digoxin was not expanded to cover further groups of people. In the absence of new evidence, the committee also agreed with the existing recommendation for combination therapy options if initial monotherapy fails, which is consistent with the committee's experience and current practice. There was a lack of evidence on long-term rate control, and the committee were aware of
